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Background
HIV-1 envelope glycoprotein (Env) is the primary target
for inducing neutralizing antibodies against the virus Env
yet only a small fraction of antibodies elicited are directed
against conserved epitopes. Thus, the antibodies pro-
duced during infection ad vaccination (to date) have been
limited in their ability to neutralize heterologous primary
isolates. Since interactions between the virus and its recep-
tor and co-receptor are critical for virus entry into the cell,
targeting conserved functional epitopes located in or near
the receptor and co-receptor binding sites may be the key
for developing an effective vaccine. We as well as others
have shown that Env-CD4 complexes are capable of
inducing broadly neutralizing antibodies, however use of
sCD4 as part of the vaccine has the potential for inducing
an autoimmune response.
Materials and methods
Therefore, we are evaluating several approaches, including
such as CD4 peptide mimetics (CD4M33), small mole-
cules and novel scaffolds such as invasin and tat (onto
which the CD4 binding domain is grafted). This may facil-
itate targeting of conserved functional epitopes on lig-
anded forms of Env and also reduce immune responses
directed towards CD4
Results
We have developed and characterized stable Env-
CD4M33 complexes and evaluated them in rabbits for
inducing neutralizing antibody responses. In a parallel
approach, we have used BMS-853 as a filter to identify 100
structurally similar small molecules, and screened them
for their ability to compete with CD4 and b12 for binding
to Env as well as their ability to induce conformational
change as reflected by enhanced binding to 17b binding.
We have so far identified three classes of small molecules
that: i) compete for CD4 binding only, ii) induce confor-
mational change in Env without competing for CD4, and
iii) compete for CD4 binding and induce conformational
changes.
Conclusion
We plan to use small molecules for stabilizing Env in lig-
anded or un-liganded forms for further evaluation of
immunogenicity in rabbits. These studies should yield
important structural information about the apo and lig-
anded structure of Env and the resulting exposure of con-
served epitopes for vaccine applications.
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